Cytel today announced the appointment of Corey Dunham as Chief Executive Officer, effective October 1, 2026. He succeeds Jovan Willford, who has decided to step down from his role as CEO.
Corey has been with Cytel for six years and has held significant leadership responsibilities across the company, most recently leading Cytel’s Functional Services and Axio businesses alongside broader commercial responsibilities. He brings deep experience in biometrics and functional services, as well as longstanding relationships with many of Cytel’s clients.
As CEO, Corey will build on Cytel’s strong scientific and quantitative foundation, with a focus on commercial excellence, project execution and operational excellence, and accelerating the application of AI across the business.
Cytel thanks Jovan for his leadership and contribution to the company and wishes him well for the future.
Share Via
Subscribe to our newsletter
Cytel
At Cytel, we cultivate a culture of continuous learning, exploration, and creativity, fostering personal growth and steering the search for ground-breaking solutions. Our team of specialized, multidisciplinary thought leaders collaborate with colleagues and clients, channeling both individual expertise and collective intelligence. Through our blog channel, Cytel Perspectives, we share valuable insights supporting every stage of your research—from the preclinical phase and trial design to market access and reimbursement. Subscribe to our newsletter today to stay informed and inspired.
Read full employee bioClaim your free 30-minute strategy session
Book a free, no-obligation strategy session with a Cytel expert to get advice on how to improve your drug’s probability of success and plot a clearer route to market.
